US FDA accepts Bristol Myers Squibb’s application for Orencia for priority review
If approved, Orencia would become the first therapy for the prevention of acute graft versus host disease (aGvHD)
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.